that it is only with subsequent investigations that we could define aetiology in 10 cases. Perhaps prognosis is good and special investigation of a 'true idiopathic pancreatitis' but how to know if it is a 'true idiopathic pancreatitis' without doing investigations? In the study of Ballinger et al., the pancreatitis was labelled idiopathic retrospectively and patients with rare causes of acute pancreatitis were excluded from the study. We think that prospectively, it is often difficult to distinguish between 'true idiopathic' and rare causes of acute pancreatitis at the time of admission and that specialised investigations are often needed to separate them. 'Idiopathic pancreatitis' is a rare diagnosis that can be accepted only after specialised investigations. We outline that three of our patients had acute pancreatitis revealing a carcinoma and that hyperparathyroidism is sometimes caused by a cancer.2

B MAES P HASTIER JP DELMOTTE Fédération des maladies de l'appareil digestif, Hôpital de l'Archet, 151 Route Saint-Antoine de Gignacière BP79-06202 Nice Cedex 3, France


Reply

EDITOR,—We have read the comments of Dr Maes and co-authors and also referred to their article that has been published in abstract form.1 They have reported on 121 consecutive cases of acute pancreatitis and the abstract includes the first 62 of these patients. In the 19 patients in whom no cause of acute pancreatitis was found on initial investigation, the authors did not state if these were first or recurrent episodes of pancreatitis. This is obviously important if comparisons are to be made with our study in which we clearly state that we have only studied patients with a first attack of idiopathic pancreatitis and thus our conclusions are only applicable to this group of patients. As Maes et al recruited consecutive patients with acute pancreatitis it is probable that a proportion were presenting with recurrent episodes.

On subsequent investigation a possible cause for acute pancreatitis was found in 10 of 19 patients in the authors' series. We are surprised that some of these aetiological factors were not identified on the first hospital admission; for instance, we would expect an antral carcinoma invading the pancreatic duct to be easily seen on the abdominal computed tomodogram. The authors do not state which drug was implicated in the aetiology of acute pancreatitis but a clinical history taken on the first admission should have identified this as a possible causative factor.

Finally, the authors state that there was a 20% recurrence rate during the follow up period but only one recurrence after the correct diagnosis was made. We are not told what specific treatment, if any, those patients with a diagnosis received and therefore it is impossible to determine if the treatment changed the natural history. It is probably only worth searching for a cause if the treatment changes the longterm outcome.

In summary, the data presented in the authors' letter and their original abstract do not change our conclusions and recommendations for the treatment of first attacks of acute idiopathic pancreatitis.

ANNE BALLINGER
ELEANOR BARNES
ELSPEITH ALSTEAD
PAUL MARICLough
Digestive Diseases Research Centre,
St Bartholomew's and The Royal London School of Medicine and Dentistry, London E1 2AT BQ


Screening for familial colorectal cancer

EDITOR,—Based upon their findings using an immunological fecal occult blood test, Crips and Heald (Gut 1996; 38: 421–5) make recommendations for screening of colorectal cancer (CRC) on the basis of a positive family history. However, current knowledge and for a reason targeted and scientifically founded approach.

Their recommendations are intended for subjects who do not have a family history suggestive of an autosomal dominant condition predisposing to colorectal cancer. How is the distinction to be made between a 'dominant pedigree' and a less than dominant pedigree? For example, one of their patients was found to have familial adenomatous polyposis (FAP). The disease is usually diagnosed at an early age, using the demonstration of germline mutations in a DNA mismatch repair gene. The affected subjects were ascertained exclusively on the basis of young age at onset of CRC.1 These examples illustrate the inadequacy of attributing lifetime risk on the basis of family history alone.2 Indeed such estimates are both crude and misleading.

The alternative approach is to offer targeted screening on the basis of the underlying genetic disorder. An approach to the correct diagnosis is achieved through the ascertainment of detailed and extended family pedigrees in which all cancer diagnoses are verified as consistent with respect to location, age at onset, and histological type. The presence of DNA microsatellite instability is an important biomarker for HNPCC, particularly when found within early onset cancers.1,2 or more cancers from the same patient or in cancers from two or more members of the same family.3 Once classical FAP, attenuated FAP,1 and HNPCC have been excluded, what is left? Apart from various rare forms of precancerous polyposis the literature hints at least one additional important autosomal dominant disorder. This has been described 'late onset familial CRC' or 'adenoma families'. Still poorly understood because features of cancers of the left colon and rectum, a modest increase in the number of adenomas, and an increased tendency for adenomas to become large and villous.1 Nevertheless the marker for this putative autosomal dominant syndrome exists at this time.

A weak family history of colorectal cancer with no distinguishing clinical, pathological or molecular features is likely to be a chance event, associated with a low lifetime risk for family members. CRC is common and affected relatives are likely to have multiple first degree relatives. Might not these relatives, perhaps representing an estimated 20% of the total population, be served through a conventional population based screening program? Obviously the success will depend on correctly assigning high risk families to particular autosomal dominant disorders. Although we currently lack full diagnostic capability in this respect, the way forward is to establish cancer family clinics that would facilitate integration of clinical, genetic, and pathological data and coordinate longterm management strategies. One shudders at the prospect of local enthusiasts linked to unlicensed gene testing outfits.

JEREMY R JASS
Faculty of Medicine and Health Science,
The University of Auckland, Private Bag 92019,
Auckland, New Zealand


Screening for colorectal cancer

EDITOR,—The article by Crips and Heald made for interesting and informative reading (Gut 1996; 38: 421–5). Their compliance rate of 60% was indeed impressive, comparing it with most other screening studies for detecting colorectal cancer. In this context, we would like to draw attention to some additional data relevant to this subject.

Hobbs and coworkers found significant differences in compliance among patients aged between 50–69 (683; 61-66%), 70 or over (343; 54-3%), and 40–49 (204; 43-8%), (p<0.001). They report that patients from the inner city practice were less likely to comply (52% versus 78%; p=0.009). They also found that fatalism, in a study among 192 elderly African Americans, was the only significant predictor of faecal occult blood testing (OR=2.0; 95% CI=1.0–4.0; p=0.014). Hlobb and coworkers noted that poverty, and education were associated with reduced attendance.

Another study found significantly higher compliance (72.8% versus 51.8%; p<0.01) among 153 patients when dietary restrictions were
not imposed. Thomas and colleagues report a significantly higher rate of screen compliance among patients living with other participants, while those who had a diagnostic colonoscopy examination with negative results had significantly lower odds of complying.

Another study showed that compliance in first degree relatives of patients with colorectal cancer was significantly higher than in spouses (69% versus 47%, p<0.01), as was among those whose relatives died recently from colorectal cancer. However they found that time since diagnosis in the index case had no effect on the compliance rate, in contrast with the findings of the authors. Finally, Neilson and coworker report that compliers are found to be of higher socioeconomic classes than persistent non-compliers, to have more personal and family experience of illness, and to visit their dentists more regularly.

These data, in conjunction with that presented by the authors, helps us better understand the factors affecting compliance, while screening for colorectal cancer.

ABHAY ANAND
Parker Hill Hematology and Oncology,
New England Baptist Hospital,
Boston, MA 02215

NAMRATA ANAND
Department of Pathology,
New England Deaconess Hospital,
Boston, MA 02215

AJAY ANAND
Division of Hematology and Oncology,
110 Francis Street, New England Deaconess Hospital,
Harvard Medical School,
Boston, MA 02215, USA

Correspondence to: Dr Ajay Anand.

Reply

EDITOR—Thank you for the opportunity to reply to the letters commenting on our publication (Gut 1996; 38: 421–5). Compliance with screening, although a complex issue, has a major impact on the ability of a programme to detect significant colorectal pathology. The additional data provided by Anand and colleagues are of clear interest.

Although we were pleased with overall uptake of screening (64-9%), our report shows—by demonstrating that some subjects were originally interested but then declined the offer of screening—that compliance is not an all-or-nothing phenomenon—that is, people may respond to an invitation but drop out when the process of screening is made clear. Obviously, the simpler the screening protocol the more likely it is to maximise uptake. This point is again made by Robinson et al in a recent report comparing one and three day HemeSelect testing who found compliance to be significantly better for the shortest test protocol. A further example of this phenomenon is shown by our screened subject who refused further intervention despite being shown to have multiple left sided polyps at an uncomfortable colonoscopy.

The implication of these findings is that compliance can yet be improved but will peak at a level at which people are simply not willing to be screened despite experiencing a high personal risk of colorectal cancer. We have recently been very disappointed to discover a 32 year old patient who was offered (and declined) screening in 1992, only to present with an obstructing, Duke's stage C caecal carcinoma in 1996. This patient is a member of an HNPPC family whose other family members are examined at St Marks' Hospital Family Cancer Clinic and who did not wish to be examined at any cost.

N P CRIPPS R J HEALD
Colorectal Research Unit, C Floor,
The North Hampshire Hospital,
Aldermaston Road,
Basingstoke, Hampshire RG21 9NA

1 Robinson MHE, Marks CG, Farrands PA,

BOOK REVIEWS


For those who want to compare the colon lengths of the short nosed bandicoot and the koala bear, but have neither the fare, nor the agility to catch the beasts for themselves—this is very definitely the book to buy and a terrific saving. However, these days a book must appeal to a less specialised market.

As the authors make clear, there is value in the study of an organ system from a non-anthropocentric viewpoint: it’s all very well for you blighters who live off the fat of the land, with your well cooked digested meals, to gloat about how much more streamlined your guts are— but what about the rest of us raw eaters, or shell eaters?—We’d like to see how long you survived on eucalyptus leaves, or how far you could fly on a diet of beetles!

On the one hoof, some of us fermenters have to retain our digesta a lot longer than you to derive any benefit from it. Furthermore, some of us are very large and have to eat a heck of a lot of ‘indigestible’ stuff to keep swarming around the sauravanas. A neat way of reducing the bulkiness of our digesta is by having a faster throughput of fermentable particulates than of fluid. However, selective retention of small particulates over fluid entails specialised gastrointestinal structures behaving effectively as filter beds. These structures are variously present in our fore, mid or hindguts and very thoroughly described in this book, with excellent diagrams.

On the other hoof—predatory birds, like hawks, although eating only the juiciest morsels, obviously cannot afford to carry around excess baggage, or they will find themselves in the relegation zone. So they fluidise, digest, and ferment their prey in their gizzards prior to absorption in a comparatively short small intestine and vestigial hindgut; non-digestible particulates are jettisoned in these species prior to absorption.

And on the third hoof—the additional advantage of non-photosynthesising, non-nosiering, non-humming, non-winging, non-grunting animal the humbird, weighing in at three grams— has an enormously high metabolic rate and therefore a continuous need for a rapidly available energy supply, has no room to accommodate either for a fermentation or digestive chamber; so it has neither caecum nor crop and lives exclusively on a fast food diet of liquid sugar.

So, we can learn a lot about animal adaptation to varying nutrition from simple microscopic examination of the gastrointestinal tract in relation to body size. This book is very good on these aspects of comparative physiology.

In this second edition, the scope of the book has been broadened to include interesting and useful chapters on digest transit and retenion, which includes a really useful discussion on digestive strategies in omnivores and herbivores; motor activity and a chapter on the evolution of the digestive system. There is a rather sparse chapter on the comparative biochemistry of digestive processes and a better one on bacterial fermentation in the gastrointestinal tract.

My main criticism of the book is its relative lack of attention to microscopic anatomy, or structure-functional correlates at the microscopic level. Perhaps this requires another book. My overall view is that this is a useful and stimulating book, well worth reading and I look forward to an enlarged third edition.

RICHARD NAFTALIN


This is the fourth edition of Epstein’s ‘The Kidney in Liver Disease’, the first having been published in 1978. The format of each is similar with multiple authorship. The book is largely devoted to problems of alcoholic cirrhosis, in particular sodium retention and renal failure. Minimal attention is given to other types of cirrhosis or to the important condition of fulminant hepatic failure. Alcoholic hepatitis, a sometimes reversible condition that may be complicated by profound renal and electrolyte disorders is not specifically mentioned.

The balance of authors leaves something to be desired—the editor is the sole author of eight of the 27 chapters and only three are written by hepatologists. The lack of hepatological input is constantly apparent throughout much of the text. Is it really appropriate for the chapters on diuretic therapy, peritoneovenous shunting or extracorporeal techniques to have been written by nephrologists? And why do we need a specialist liver unit with an interest in these subjects would have far more
Screening for colorectal cancer.

A Anand, N Anand and A Anand

*Gut* 1996 39: 497-498
doi: 10.1136/gut.39.3.497-b

Updated information and services can be found at:
http://gut.bmj.com/content/39/3/497.3.citation

**Email alerting service**

*These include:*

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/